Increased demand is causing the shortage that has hit five drugmakers, according to the FDA.
Teva Pharmaceuticals “is continuing to produce to planned demand” for nine products, Novartis’ Sandoz has four on allocation, Rising Pharma has two in short supply but available, Hikma Pharmaceuticals has four “available for current customers” and Aurobindo has four on allocation.
Amoxicillin is an antibiotic that the CDC recommends as a “first-line therapy” for multiple pediatric infections.
The FDA did not list resupply dates, but the ASHP reported all of the products are expected to return to normal levels by the end of 2022. In the ASHP’s post in late October, the shortage included 41 products from Teva, Sandoz and Rising Pharma.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
